← All trials
NCT07022483
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Mar 23, 2032
- Completion date
- Mar 23, 2032
- First posted
- Jun 15, 2025
- Last posted
- Nov 3, 2025
- Enrollment
- 710
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Daiichi SankyoLead sponsor
- AstraZenecaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.